Qiagen NV (QGEN)
44.27
+0.13
(+0.29%)
USD |
NYSE |
Mar 19, 09:44
Qiagen Cash from Operations (TTM)
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2022 | 715.26M |
September 30, 2022 | 789.40M |
June 30, 2022 | 733.34M |
March 31, 2022 | 717.78M |
December 31, 2021 | 639.00M |
September 30, 2021 | 710.26M |
June 30, 2021 | 592.24M |
March 31, 2021 | 570.52M |
December 31, 2020 | 457.81M |
September 30, 2020 | 297.52M |
June 30, 2020 | 354.22M |
March 31, 2020 | 302.02M |
December 31, 2019 | 330.84M |
September 30, 2019 | 331.92M |
June 30, 2019 | 320.47M |
March 31, 2019 | 356.02M |
December 31, 2018 | 359.50M |
September 30, 2018 | 325.05M |
June 30, 2018 | 323.50M |
March 31, 2018 | 274.84M |
December 31, 2017 | 286.78M |
September 30, 2017 | 310.74M |
June 30, 2017 | 323.35M |
March 31, 2017 | 353.07M |
December 31, 2016 | 341.60M |
Date | Value |
---|---|
September 30, 2016 | 328.34M |
June 30, 2016 | 330.59M |
March 31, 2016 | 303.34M |
December 31, 2015 | 317.50M |
September 30, 2015 | 309.75M |
June 30, 2015 | 303.42M |
March 31, 2015 | 305.20M |
December 31, 2014 | 287.96M |
September 30, 2014 | 291.14M |
June 30, 2014 | 284.34M |
March 31, 2014 | 258.69M |
December 31, 2013 | 258.96M |
September 30, 2013 | 246.68M |
June 30, 2013 | 238.67M |
March 31, 2013 | 279.63M |
December 31, 2012 | 244.88M |
September 30, 2012 | 254.64M |
June 30, 2012 | 238.76M |
March 31, 2012 | 205.86M |
December 31, 2011 | 244.78M |
September 30, 2011 | 250.92M |
June 30, 2011 | 280.33M |
March 31, 2011 | 271.24M |
December 31, 2010 | 250.75M |
September 30, 2010 | 217.59M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
297.52M
Minimum
Sep 2020
789.40M
Maximum
Sep 2022
513.66M
Average
514.16M
Median
Cash from Operations (TTM) Benchmarks
MoonLake Immunotherapeutics | -42.78M |
Thermo Fisher Scientific Inc | 8.406B |
uniQure NV | -145.93M |
ProQR Therapeutics NV | 23.33M |
Merus NV | -142.21M |